Literature DB >> 11685267

Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients.

A Schubach1, T Cuzzi-Maya, A V Oliveira, A Sartori, M P de Oliveira-Neto, M S Mattos, M L Araújo, W J Souza, F Haddad, M de A Perez, R S Pacheco, H Momen, S G Coutinho, M C de Almeida Marzochi, K B Marzochi, S C da Costa.   

Abstract

Cutaneous biopsies (n = 94) obtained from 88 patients with American tegumentary leishmaniasis were studied by conventional and immunohistochemical techniques. Specimens were distributed as active lesions of cutaneous leishmaniasis (n = 53) (Group I), cicatricial lesions of cutaneous leishmaniasis (n = 35) (Group II) and suggestive scars of healed mucosal leishmaniasis patients (n = 6) (Group III). In addition, active cutaneous lesions of other etiology (n = 24) (Group C1) and cutaneous scars not related to leishmaniasis (n = 10) (Group C2) were also included in the protocol. Amastigotes in Group I biopsies were detected by routine histopathological exam (30.2%), imprint (28.2%), culture (43.4%), immunofluorescence (41.4%) and immunoperoxidase (58.5%) techniques; and by the five methods together (79.3%). In Group II, 5.7% of cultures were positive. Leishmanial antigen was also seen in the cytoplasm of macrophages and giant cells (cellular pattern), vessel walls (vascular pattern) and dermal nerves (neural pattern). Positive reaction was detected in 49 (92.5%), 20 (57%) and 4 (67%) biopsies of Groups I, II and III, respectively. Antigen persistency in cicatricial tissue may be related to immunoprotection or, on the contrary, to the development of late lesions. We suggest that the cellular, vascular and neural patterns could be applied in the immunodiagnosis of active and cicatricial lesions in which leishmaniasis is suspected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685267     DOI: 10.1590/s0074-02762001000700018

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  13 in total

1.  Is Leishmania (Viannia) braziliensis preferentially restricted to the cutaneous lesions of naturally infected dogs?

Authors:  Maria de Fátima Madeira; Armando de O Schubach; Tânia M P Schubach; Cathia M B Serra; Sandro A Pereira; Fabiano B Figueiredo; Eliame Mouta Confort; Leonardo P Quintella; Mauro C A Marzochi
Journal:  Parasitol Res       Date:  2005-06-29       Impact factor: 2.289

2.  Imaging Leishmania major Antigens in Experimentally Infected Macrophages and Dermal Scrapings from Cutaneous Leishmaniasis Lesions in Tunisia.

Authors:  Nasreddine Saïdi; Yousr Galaï; Meriem Ben-Abid; Thouraya Boussoffara; Ines Ben-Sghaier; Karim Aoun; Aïda Bouratbine
Journal:  Microorganisms       Date:  2022-06-04

3.  Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.

Authors:  Carvel Suprien; Paulo N Rocha; Marina Teixeira; Lucas P Carvalho; Luiz H Guimarães; Toby Bonvoisin; Paulo R L Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

4.  American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi.

Authors:  Cecilia Parodi; María F García Bustos; Alejandra Barrio; Federico Ramos; Ana G González Prieto; María C Mora; Patricia Baré; Miguel A Basombrío; María M de Elizalde de Bracco
Journal:  Med Microbiol Immunol       Date:  2016-04-04       Impact factor: 3.402

5.  Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).

Authors:  Erica de Camargo Ferreira E Vasconcellos; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhaes de Oliveira; Rilza Beatriz Azeredo-Coutinho; Fátima da Conceição Silva; Mariza de Matos Salgueiro; João Soares Moreira; Maria de Fátima Madeira; Cibele Baptista; Cláudia Maria Valete-Rosalino
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

6.  Recombinant Leishmania infantum heat shock protein 83 for the serodiagnosis of cutaneous, mucosal, and visceral leishmaniases.

Authors:  Beatriz Julieta Celeste; Maria Carmen Arroyo Sanchez; Eduardo Milton Ramos-Sanchez; Luiz Guilherme M Castro; Francisco Assis Lima Costa; Hiro Goto
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

7.  Characterization of the Histopathologic Features in Patients in the Early and Late Phases of Cutaneous Leishmaniasis.

Authors:  Maíra G Saldanha; Adriano Queiroz; Paulo Roberto L Machado; Lucas P de Carvalho; Phillip Scott; Edgar M de Carvalho Filho; Sérgio Arruda
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

8.  American tegumentary leishmaniasis: effectiveness of an immunohistochemical protocol for the detection of Leishmania in skin.

Authors:  Cibele Fontes Alves; Cintia Fontes Alves; Maria Marta Figueiredo; Carolina Carvalho Souza; George Luiz Lins Machado-Coelho; Maria Norma Melo; Washington Luiz Tafuri; Pedro Raso; Rodrigo Pedro Soares; Wagner Luiz Tafuri
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

9.  Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection.

Authors:  R B G Azeredo-Coutinho; D C S Matos; J A C Nery; C M Valete-Rosalino; S C F Mendonça
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

10.  Voice disorders in mucosal leishmaniasis.

Authors:  Ana Cristina Nunes Ruas; Márcia Mendonça Lucena; Ananda Dutra da Costa; Jéssica Rafael Vieira; Maria Helena de Araújo-Melo; Benivaldo Ramos Ferreira Terceiro; Tania Salgado de Sousa Torraca; Armando de Oliveira Schubach; Claudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.